Literature DB >> 773824

Serum chemotactic inhibitory activity: heat activation of chemotactic inhibition.

D E Epps, R C Williams.   

Abstract

Serum chemotactic inhibitory activity (CIA) was studied in 46 patients with various systemic diseases, using a system consisting of normal human leukocytes as indicator cells and 10% fresh normal serum as a control chemotactic attractant. It was shown, as previously reported, that an association exists between CIA and skin test anergy. Heat treatment of sera at 56 C for 30 min increased both the incidence and the degree of chemotactic inhibition observed in these patients. The effects of heat treatment of sera containing CIA on other chemotactic attractants (C3a, bacteria-derived chemotactic factor (BF), and casein) are shown. Before heat treatment, some sera suppressed chemotaxis mediated by BF in the absence of suppression of normal serum-mediated chemotaxis, indicating the possible involvement of more than one system of inhibition. Multiple systems were further supported by data indicating that room temperature incubation resulted in a loss of CIA as measured by normal serum-mediated chemotoxis with no apparent decrease in the inhibition of BF -mediated chemotaxis. Separation of sera containing CIA by Sephadex G-200 showed chemotactic inhibitory activity to be increased in both the void volume region. Experiments showed that heat treating before separation resulted in similar increases in both peaks, implying the presence of an antagonist to CIA. Experiments demonstrating that sera containing CIA do not suppress casein-mediated chemotaxis by means of an irreversible inactivation of chemotactic factor are included along with experiments demonstrating a cellular mode of action. The possible presence of two systems of chemotactic inhibition, one acting directly upon chemotactic factors and one interacting with the responding cell, are discussed.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 773824      PMCID: PMC420672          DOI: 10.1128/iai.13.3.741-749.1976

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  18 in total

1.  Immunoglobulins cytophilic for human lymphocytes, monocytes, and neutrophils.

Authors:  D A Lawrence; W O Weigle; H L Spiegelberg
Journal:  J Clin Invest       Date:  1975-02       Impact factor: 14.808

2.  Suppression of chemotatic activity of human neutrophils by streptolysin O.

Authors:  B R Andersen; D E Van Epps
Journal:  J Infect Dis       Date:  1972-04       Impact factor: 5.226

3.  A serum inhibitor of leukotaxis in a child with recurrent infections.

Authors:  C W Smith; J C Hollers; E Dupree; A S Goldman; R A Lord
Journal:  J Lab Clin Med       Date:  1972-06

4.  Antibody-agarose immunoadsorbents: complete removal of classes of immunoglobulins from serum.

Authors:  M Mannik; D E Stage
Journal:  J Immunol       Date:  1971-06       Impact factor: 5.422

5.  Impaired leucotactic responsiveness in a child with recurrent infections.

Authors:  P A Ward; R J Schlegel
Journal:  Lancet       Date:  1969-08-16       Impact factor: 79.321

6.  Two distinct chemotactic factor inactivators in human serum.

Authors:  G Till; P A Ward
Journal:  J Immunol       Date:  1975-02       Impact factor: 5.422

7.  Inhibitors of leukocyte chemotaxis in alcoholic liver disease.

Authors:  D E Van Epps; R G Strickland; R C Williams
Journal:  Am J Med       Date:  1975-08       Impact factor: 4.965

8.  Defective regulation of chemotaxis in cirrhosis.

Authors:  E C Maderazo; P A Ward; R Quintiliani
Journal:  J Lab Clin Med       Date:  1975-04

9.  The fibrinolytic pathway of human plasma. II. The generation of chemotactic activity by activation of plasminogen proactivator.

Authors:  A P Kaplan; E J Goetzl; K F Austen
Journal:  J Clin Invest       Date:  1973-10       Impact factor: 14.808

10.  Chemotactic factor inactivator in normal human serum.

Authors:  J L Berenberg; P A Ward
Journal:  J Clin Invest       Date:  1973-05       Impact factor: 14.808

View more
  8 in total

1.  Impairment of neutrophil chemotaxis by serum from patients with chronic lymphoproliferative disease.

Authors:  U Jayaswal; S Roper; S Roath
Journal:  J Clin Pathol       Date:  1983-04       Impact factor: 3.411

2.  Defective neutrophil chemotaxis in juvenile periodontitis.

Authors:  R A Clark; R C Page; G Wilde
Journal:  Infect Immun       Date:  1977-12       Impact factor: 3.441

3.  Casein-mediated neutrophil chemotaxis: a parallel between surface binding and chemotaxis.

Authors:  D E Van Epps; A D Bankhurst; R C Williams
Journal:  Inflammation       Date:  1977-06       Impact factor: 4.092

4.  Serum inhibitor of C5 fragment-mediated polymorphonuclear leukocyte chemotaxis associated with chronic hemodialysis.

Authors:  S E Goldblum; D E Van Epps; W P Reed
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

5.  Neutrophil chemotaxis dysfunction in human periodontitis.

Authors:  T E Van Dyke; H U Horoszewicz; L J Cianciola; R J Genco
Journal:  Infect Immun       Date:  1980-01       Impact factor: 3.441

6.  Defective polymorphonuclear leucocyte chemotaxis in rheumatoid arthritis associated with a serum inhibitor.

Authors:  S M Hanlon; G S Panayi; R Laurent
Journal:  Ann Rheum Dis       Date:  1980-02       Impact factor: 19.103

7.  Differential effects of serum heat treatment on chemotaxis and phagocytosis by human neutrophils.

Authors:  Alexander R Mankovich; Cheng-Yuk Lee; Volkmar Heinrich
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240

8.  Suppression of leukocyte chemotaxis by human IgA myeloma components.

Authors:  D E Van Epps; R C Williams
Journal:  J Exp Med       Date:  1976-11-02       Impact factor: 14.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.